all report title image
  • Published On : Jan 2022
  • Code : CMI4892
  • Industry : Pharmaceutical
  • Pages : 111
  • Formats :

Wounds are the injuries that tear the skin or tissues by punctured skin, scratches, cuts, and scrapes. Wounds mostly happen accidently, but in rare cases sutures, stitches, or surgery also cause wounds. Wound healing is nothing but healing of the skin. It begins immediately after an injury. Wounds can be classified into acute wounds and chronic wounds. Acute wounds takes only a few weeks to completely heal while chronic wounds takes few months to heal completely. Chronic wounds include pressure sores and venous leg ulcers. Wound healing, as a normal biological process in the human body, is achieved through four precisely and highly programmed phases such as hemostasis, inflammation, proliferation, and remodeling. For a wound to heal successfully, all four phases must occur in the proper sequence and time frame.

The Colombia wound care biologics market is estimated to be valued at US$ 9.6 million in 2021 and is expected to exhibit a CAGR of 5.4% over the forecast period (2021-2028).

The increasing product launches are expected to drive the market growth over the forecast period.

For instance, in September 2020, MiMedx Group, Inc. an industry leader in advanced wound care and an emerging therapeutic biologics company, launched EpiCord Expandable. EpiCord Expandable is clinically efficient to use for the treatment of diabetic foot ulcers.

Figure 1. Colombia Wound Care Biologics Market Value (%), By Product Type, 2021

Colombia Wound Care Biologics  | Coherent Market Insights

The increasing mergers and acquisitions by the key players is expected to drive the market growth over the forecast period.

For instance, in June 2018, Acelity L.P. Inc., the world’s largest wound care company and Crawford Healthcare U.K.-based advanced wound care and dermatology company entered into an acquisition agreement. Under which Acelity would acquire Crawford with all of its assets. Therefore, this acquisition would expand Acelity’s portfolio of advanced wound dressings.

CMI table icon

Colombia Wound Care Biologics Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 9.6 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 5.4% 2028 Value Projection: US$ 14.8 Mn
Geographies covered:
  • Colombia
Segments covered:
  • By Product Type: Biologic Skin Substitutes, Enzyme Based Formulations, Growth Factors
  • By Application: Chronic Wounds (Diabetic Foot Ulcer, Venous Leg Ulcer, Pressure Ulcer), Acute Wounds (Surgical Wounds, Burns), (Others include rare blood diseases)
  • By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Home Care SettingsOthers
Companies covered:

Smith & Nephew, Plc, Organogenesis, Inc., Integra Life Sciences Corporation, MiMedx Group, Inc., Skye Biologics, Inc., Amino Technology LLC, Osiris Therapeutics, Inc., Alphatec Holdings, Inc. Mallinckrodt Plc., Amniox Medical, Inc., Acelity L.P. Inc., ConvaTec Group Plc, Generex Biotechnology Corporation, and Olaregen Therapeutix Inc.

Growth Drivers:
  • Increasing prevalence of diabetes and diabetic foot
  • Rising medical tourism, favoring the demand for wound care biologic products,
  • New product launches and approvals
  • Rising research and development activities for the development of novel technology for the treatment of wound
Restraints & Challenges:
  • Increasing adoption of alternative wound care products  
  • High cost of the wound care biologics products

Figure 2. Colombia Wound Care Biologics Market Value (%), By Application, 2021

Colombia Wound Care Biologics  | Coherent Market Insights

The increasing product approvals are expected to drive the market growth over the forecast period.

For instance, in July 2018, ConvaTec Group Plc, a leading global medical products and technologies company, received the U.S. Food and Drug Administration (FDA) approval for its innovative and advanced antimicrobial dressing AQUACEL Ag Advantage dressing for wound management.

Colombia Wound Care Biologics Market– Impact of Coronavirus (COVID-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on November 25, 2021. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 258,830,438 cases and 5,174,646 deaths due to coronavirus (COVID-19) were reported till July 25, 2021, across the globe.

The COVID-19 pandemic and lockdown in various countries across the globe has negatively impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. Likewise, COVID-19 pandemic has made a negative impact on Colombia wound care biologics market, owing to reduced access to wound management clinics due to lockdown.

Colombia Wound Care Biologics Market - Restraint

Increasing adoption of alternative wound care products and high cost of the wound care biologics products are expected to hinder growth of the Colombia wound care biologics market over the forecast period. The wound care biologic products are relatively expensive, significantly contributing towards cost of total wound management procedure, thereby deterring the patients from seeking advanced wound care. This is a major factor responsible for increasing inclination of patients towards conventional wound care management techniques such as traditional and antimicrobial dressing.

For instance, Collagenase SANTYL Ointment is the only enzymatic debride costing for around US$ 244 for 30 gm quantity. Furthermore, skin substitute products and engineered growth factor could find it difficult to make headway into the Colombian market as these are specialized products with cost that may be difficult to afford.

Traditional wound care products such as polymer dressings, cotton balls, and emulsion are still a common approach for wound healing, owing to its easy application, high accessibility to surgical hospitals, and low costs. Moreover, the medical professionals majorly prefer advanced therapies for wound management such as negative pressure wound therapy and hyperbaric therapy to minimize the occurrence of allergic reactions caused due to skin substitutes tissues. Alternative therapies such as negative pressure wound therapies and others are also proved to have higher efficacy in treating chronic wounds with well-established positive clinical results.

Key Players

Major players operating in the Colombia wound care biologics market include Smith & Nephew, Plc, Organogenesis, Inc., Integra Life Sciences Corporation, MiMedx Group, Inc., Skye Biologics, Inc., Amino Technology LLC, Osiris Therapeutics, Inc., Alphatec Holdings, Inc. Mallinckrodt Plc., Amniox Medical, Inc., Acelity L.P. Inc., ConvaTec Group Plc, Generex Biotechnology Corporation, and Olaregen Therapeutix Inc.

Wound is an injury to the body that typically involves breaking of a skin membrane or tearing of soft body tissue and usually damage to underneath tissues. Wounds can be categorize as chronic wounds and acute wounds.

Chronic wound is a symptom of disease, deficiency, ailment or infection that is characterized by no signs of significant healing over a prolonged period of time. Bariatric patients, diabetic patients or those with venous insufficiency are at high risk of developing chronic wounds. The most common chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers are treated using biologic skin substitutes and are characterized by non-healing capability for over 30 days.

Acute wounds are observed in all patients with traumatic and surgical wounds, superficial burns or abrasions. Acute wounds need to be handled efficiently as poor wound care or delay in the process could lead to chronic wounds. Management of acute wound includes examination for underlying injuries, removal of harmful debris or necrotic tissue, control of bacterial growth, and appropriate wound closure.

Wound healing is nothing but the healing of the skin immediately after an injury. Wound healing is a biological process which involves four phases such as hemostasis, inflammation, proliferation, and remodeling. All these four phases must takes place in the proper time frame and sequence to heal the wound successfully.

Market Dynamics

Increasing prevalence of diabetes and diabetic foot, rising medical tourism, favoring the demand for wound care biologic products, new product launches and commercial activities in wound care biologics, rising incidences of chronic wounds and ulcers, rising research and development activities for the development of novel technology for the treatment of wound, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the Colombia wound care biologics market over the forecast period.

For instance, according to the statistics provided by the International Diabetes Federation, total cases of diabetes in adults were found to be 2,836,500 in Colombia in May 2020.

Key features of the study:

  • This report provides in-depth analysis of the Colombia wound care biologics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Colombia wound care biologics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Smith & Nephew, Plc, Organogenesis, Inc., Integra Life Sciences Corporation, MiMedx Group, Inc., Skye Biologics, Inc., Amino Technology LLC, Osiris Therapeutics, Inc., Alphatec Holdings, Inc. Mallinckrodt Plc., Amniox Medical, Inc., Acelity L.P. Inc., ConvaTec Group Plc, Generex Biotechnology Corporation, and Olaregen Therapeutix Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The Colombia wound care biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Colombia wound care biologics market

Detailed Segmentation:

  • Colombia Wound Care Biologics Market, By Product Type:
    • Biologic Skin Substitutes
    • Enzyme Based Formulations
    • Growth Factors
  • Colombia Wound Care Biologics Market, By Application:
    • Chronic Wounds
      • Diabetic Foot Ulcer
      • Venous Leg Ulcer
      • Pressure Ulcer
    • Acute Wounds
      • Surgical Wounds
      • Burns
  • Colombia Wound Care Biologics Market, By End User:
    • Hospitals
    • Clinics
    • Ambulatory Surgical Centers
    • Home Care Settings
  • Company Profiles
    • Smith & Nephew, Plc *
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Organogenesis, Inc.
    • Integra Life Sciences Corporation
    • MiMedx Group, Inc.
    • Skye Biologics, Inc.
    • Amino Technology LLC
    • Osiris Therapeutics, Inc.
    • Alphatec Holdings, Inc.
    • Mallinckrodt Plc.
    • Amniox Medical, Inc.
    • Acelity L.P. Inc.
    • ConvaTec Group Plc.
    • Generex Biotechnology Corporation
    • Olaregen Therapeutix Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The Colombia wound care biologics market size is estimated to be valued at US$ 9.6 million in 2021 and is expected to exhibit a CAGR of 5.4% between 2021 and 2028.
Increasing prevalence of diabetes and diabetic foot, rising medical tourism, favoring the demand for wound care biologic products, new product launches, and commercial activities in wound care biologics, rising incidences of chronic wounds and ulcers, rising research and development activities for the development of novel technology for the treatment of wound, are expected to drive the market growth over the forecast period.
Biologic skin substitutes segment is expected to hold major market share, owing to increasing product launches during the forecast period.
Major factors hampering growth of the market include increasing adoption of alternative wound care products and high cost of the wound care biologics products.
Major players operating in the market include Smith & Nephew, Plc, Organogenesis, Inc., Integra Life Sciences Corporation, MiMedx Group, Inc., Skye Biologics, Inc., Amino Technology LLC, Osiris Therapeutics, Inc., Alphatec Holdings, Inc. Mallinckrodt Plc., Amniox Medical, Inc., Acelity L.P. Inc., ConvaTec Group Plc, Generex Biotechnology Corporation, and Olaregen Therapeutix Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo